Low-molecular-weight heparin in oncology

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2789-2793

  Zacharski, Leo R ^a   Loynes, James T ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Department of Hematology Oncology ^*  (United States)

Author keywords

Antithrombotic; Cancer; Dalteparin; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HUMAN; HYPERCOAGULABILITY; INTRAVENOUS CATHETER; LUNG CARCINOMA; META ANALYSIS; MUCINOUS CARCINOMA; ONCOLOGY; OUTCOMES RESEARCH; PANCREAS CARCINOMA; PELVIS SURGERY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; THROMBOEMBOLISM;

EID: 0043069472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Agnelli G: Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 78: 117-20, 1997.
2. Lee AY and Levine MN: The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 25: 137-145, 1999.
3. Prandoni P and Piccioli A: Venous thromboembolism and cancer: a two-way clinical association. Front Biosci 1: e12-20, 1997.
4. Donati MB: Cancer and thrombosis. Haemostasis 24: 128-131, 1994.
5. Prandoni P, Piccioli A and Girolami A: Cancer and venous thromboembolism: an overview. Haematologica 84: 437-445, 1999.
6. Rickles FR and Falanga A: Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102: V215-224, 2001.
7. Zacharski LR, Ornstein DL and Mamourian AC: Low-molecular-weight heparin and cancer. Semin Thromb Hemost 26 (Suppl 1): 69-77, 2000.
8. Monreal M, Fernandez-Llamazares J, Perandreu J et al: Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 78: 1316-1318, 1997.
9. Prandoni P, Lensing AW, Buller HR et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327: 1128-1133, 1992.
10. Prandoni P: Cancer and thromboembolic disease: how important is the risk of thrombosis? Cancer Treat Rev 28: 133-136, 2002.
11. Lee AY and Levine MN: Management of venous thromboembolism in cancer patients. Oncology (Huntingt) 14: 409-421, 2000.
12. Levine MN and Lee AY: Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 25: c245-249, 1999.
13. Zacharski LR and Ornstein DL: Heparin and cancer. Thromb Haemost 80: 10-23, 1998.
14. Derbyshire EJ, Comin GA, Yang YC et al: Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids. Int J Cancer 63: 694-701, 1995.
15. Folkman J, Langer R, Linhardt RJ et al: Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719-725, 1983.
16. Goerner A: The influence of anticlotting agents on transplantation and growth of tumour tissue. J Lab Clin Med 16: 369-372, 1930.
17. Thorpe PE, Derbyshire EJ, Andrade SP et al: Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res 53: 3000-3007, 1993.
18. Hutten BA, Prins MH, Gent M et al: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18: 3078-3083, 2000.
19. Ambrus JL, Ambrus CM, Mink IB et al: Causes of death in cancer patients. J Med 6: 61-64, 1975.
20. Sproul E: Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34: 566-585, 1938.
21. Huber O, Bounameaux H, Borst F et al: Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 127: 310-313, 1992.
22. Walsh DC and Kakkar AK: Thromboembolism in brain tumors. Curr Opin Pulm Med 7: 326-331, 2001.
23. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 12-26; 162(15): 1729-35, 2002.
24. Green D, Hull RD, Brant R et al: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339: 1476, 1992.
25. Siragusa S, Cosmi B, Piovella F et al: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100: 269-277, 1996.
26. Hettiarachchi RJ, Smorenburg SM, Ginsberg J et al: Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82: 947-952, 1999.
27. von Tempelhoff G F, Harenberg J, Niemann F et al: Effect of low-molecular-weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 16: 815-824, 2000.
28. Bergqvist D, Burmark US, Flordal PA et al: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 82: 496-501, 1995.
29. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 84: 1099-1103, 1997.
30. Bergqvist D, Agnelli G, Cohen AT et al: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975-980, 2002.
31. Rasmussen M, Jorgensen L, Wille-Jorgensen P et al: Prolonged prophylaxis with dalteparin after major abdominal surgery, Vol. Presented at the XVIII Congress of The International Society on Thrombosis and Haemostasis 6-12 July 2001, pp. Abstract OC1733.
32. Schwarz RE, Coit DG and Groeger JS: Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 7: 441-449, 2000.
33. Monreal M, Alastrue A, Rull M et al: Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75: 251-253, 1996.
34. Lersch C, Kotowa W and Janssen D: Thromboembolic prophylaxis with dalteparin-na (fragmin) in oncological patients after port implantations. TumorDiagnostik & Therapie 23: 104-110, 2002.
35. Tesselaar M, Ouwerkerk J, Rosendaal F and Osanto S: Prophylaxis with low molecular weight heparin reduces the risk for catheter-related venous thrombosis in cancer patients in centrally, but not peripherally, inserted central venous catheters. American Society of Clinical Oncology, Abstract number 1584, 2001.
36. Levine MN, Lee AY, Baker RI et al: A randomised trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Presented at the 44th Annual Meeting of the American Society of Hematology 6-10 December 2002:Abstract 298.
37. Kakkar AK, Kadziola Z, Williamson MN et al: Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Presented at the 44th Annual Meeting of the American, Society of Hematology 6-10 December 2002:Abstract 557.
38. Altinbas M, Coskun HS, Er O et al: Prospective randomised study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV) +/- low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). Proc ASCO 20: 321a, 2001.